FDA Approves Bondlido (lidocaine topical system) for the Treatment of Post-Herpetic Neuralgia
MEDRx announced the U.S. Food and Drug Administration (FDA) approval of Bondlido, a lidocaine patch MEDRx Group and D. Western Therapeutics Institute, Inc. has jointly developed, in adults for relief of pain associated with post-herpetic neuralgia (PHN). Going forward, preparations for the launch will be made, including the selection of sales partners, with sales planned to begin in the US in the first half of 2026.